ÕÑÑÜÐÂÒ©³öϯµÚ64½ìÃÀ¹úSOTÄê»á²¢×÷ÕªÒª·ÖÏí
2025-01-22
µÚ64½ìÃÀ¹ú¶¾Àíѧ»á£¨SOT£©Äê»á½«ÓÚÃÀ¹ú¶«²¿Ê±¼ä2025Äê3ÔÂ16ÈÕ-20ÈÕÔÚÃÀ¹ú°ÂÀ¼¶à¾ÙÐС£¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»£¾Û»áΪÆÚÎåÌ죬£¬£¬£¬£¬£¬£¬£¬ÎüÒýÁË500Óàλ¶¾Àíѧר¼Ò¾Û½¹Ç°ÑØ»úÖÆ¡¢Î£º¦ÆÀ¹ÀµÈÒéÌâ¾ÙÐÐÉîÈë×êÑУ¬£¬£¬£¬£¬£¬£¬£¬³¬ 2000 ·ÝÌåÍâ¡¢ÌåÄÚ¶¾ÀíѧЧ¹ûº£±¨²ÎÕ¹£¬£¬£¬£¬£¬£¬£¬£¬Ôö½øÑ§Êõ½»Á÷¡£¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»£¾Û»á»ã¾ÛÈ«Çò 50 ¶à¹ú¡¢³¬8000Ãû¿ÆÑÐÖ°Ô±¡¢´ÓÒµÕß¼°ÆóÒµÖ÷¸É£¬£¬£¬£¬£¬£¬£¬£¬´î½¨¿çÇøÓòÏàÖúƽ̨£¬£¬£¬£¬£¬£¬£¬£¬Íƶ¯ÐÐÒµÉú³¤¡£¡£¡£¡£¡£¡£¡£¡£
ÕÑÑÜÐÂÒ©Ê×ϯ¿ÆÑ§¼ÒÒ¦´óÁÖ²©Ê¿¡¢ÕÑÑÜÐÂÒ©¸±×ܲüæÁªÏ¯Ê×ϯÊÖÒÕ¹ÙÕÅÓÀ±ó²©Ê¿½«³öϯ´Ë´Î¾Û»á¡£¡£¡£¡£¡£¡£¡£¡£½ìʱ£¬£¬£¬£¬£¬£¬£¬£¬ÕÑÑÜÐÂÒ©½«¾ÙÐÐ7¸öÖ÷ÌâµÄ±Ú±¨·ÖÏíÓë½²ÑÝ£¬£¬£¬£¬£¬£¬£¬£¬¼ÓÈëС×é¾Û»áµÄÖ÷Ìâ·ÖÏí¡£¡£¡£¡£¡£¡£¡£¡£ÕÑÑÜÐÂÒ© JOINN/BiomereÉèÁ¢ÁËչ̨£¨Õ¹Î»ºÅ#1351£©£¬£¬£¬£¬£¬£¬£¬£¬ÏêϸÏÈÈݹ«Ë¾ÔÚÒ©ÎïÈ«ÉúÃüÖÜÆÚÖеĽâ¾ö¼Æ»®£¬£¬£¬£¬£¬£¬£¬£¬½Ó´ýÒµ½çͬÈÊǰÀ´½»Á÷Ǣ̸¡£¡£¡£¡£¡£¡£¡£¡£
| רÌⱨ¸æ £¨Session Presentation£©
±¨¸æÖ÷Ì⣨Session Title£©£ºAdvanced Capabilities for Ocular Drug Development Using NHP Models£¨·ÇÈËÁ鳤ÀදÎïÓÃÓÚÑÛ¿ÆÐÂÒ©Ñз¢£©
±¨¸æÊ±¼ä£¨Date & Time£©£º2024Äê3ÔÂ17ÈÕ 13:45-14:45£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 17th (Mon), 1:45-2:45pm
±¨¸æËùÔÚ£¨Location£©£º³ÈÏØ¾Û»áÖÐÐÄ W208B¾Û»áÊÒ£¨West Concourse of the Orange County Convention Center£¬£¬£¬£¬£¬£¬£¬£¬Room W208B£©
Ö÷½²ÈË£¨Presenting Author£©£ºÐ»ÍòÀ¤²©Ê¿£¬£¬£¬£¬£¬£¬£¬£¬ÕÑÑÜ£¨ËÕÖÝ£©ÑÛ¿Æ×ܼà
| Ö°ÒµÍýÏë½²×ù £¨AACT Career Workshop£©
±¨¸æÊ±¼ä£¨Date & Time£©£º2024Äê3ÔÂ17ÈÕ 17:00-18:00£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 17th (Mon), 5:00-6:00 pm
±¨¸æËùÔÚ£¨Location£©£º¿ÔÃÂùÝεÂÃ×¶ûÊ®ºÅÌü£¨Windermere Ballroom X, Hyatt Regency£©
Ö÷½²ÈË£¨Presenting Author£©£ºÕÅÓÀ±ó²©Ê¿£¬£¬£¬£¬£¬£¬£¬£¬¸±×ܲã¨VP£©¼æÁªÏ¯Ê×ϯÊÖÒÕ¹Ù£¨CO-CTO£©
Ö÷½²È˼ò½é£¨Brief£©£º½áÒµÓÚÖйúũҵ´óѧ»ñÊÞҽѧרҵѧλ,ºóÓÚÃÀ¹ú¶í¿ËÀºÉÂíÖÝÁ¢´óѧ»ñµÃ¶¾Àíѧ²©Ê¿Ñ§Î»¡£¡£¡£¡£¡£¡£¡£¡£ËûÔÚFDAµÄ¹ú¼Ò¶¾ÀíѧÑо¿ÖÐÐÄNCTRÍê³É²©Ê¿ºóÑо¿£¬£¬£¬£¬£¬£¬£¬£¬ËæºóÕýʽÈëÖ°FDA×÷Ϊ¶¾ÀíѧÏîÄ¿ÈÏÕæÈ˽¨Éè²¢Ïòµ¼FDAµÄÄÉÃ×¶¾ÀíѧʵÑéÊÒ¼ÓÈëÁËÊýÏîÐÂÒ©ºÍҩеÏà¹ØÏîÄ¿Ñо¿¼°Çå¾²ÐÔÆÀ¼Û¡£¡£¡£¡£¡£¡£¡£¡£ÔÚ15ÄêFDAÖ°ÒµÉúÑÄÖУ¬£¬£¬£¬£¬£¬£¬£¬ÆäÔÚÁ¢ÒìÒ©ÉóÆÀÖÐÐÄ×÷Ϊ·ÇÁÙ´²¸ß¼¶ÉóÆÀר¼ÒÈÏÕæÁËÊý°Ù¸öÐÂÒ©¿ª·¢µÄINDºÍÊýÊ®¿îÐÂÒ©µÄÉÏÊÐÉóÅúÊÂÇ飬£¬£¬£¬£¬£¬£¬£¬²¢¼ÓÈë¶àÏîFDAÐÂÒ©ÆÀ¼ÛÖ¸ÄÏµÄÆð²ÝÖÆ¶©µÈ¡£¡£¡£¡£¡£¡£¡£¡£Òò´ËÕŲ©Ê¿ÔøÈÙ»ñFDAÓÅÒìÇàÄê¿ÆÑ§¼Ò½±ºÍFDAÓÅÒìЧÀͽ±¡£¡£¡£¡£¡£¡£¡£¡£ËûÔøÈÎÖ°ÓÚºÉÀ¼Ó¢ÌØÍþ¹ú¼ÊÓÐÏÞ¹«Ë¾(ÏÖÁ¥Êô Merck·Ö²¿)ÈÏÕæ²úÆ·µÄÊг¡ÊÖÒÕÖ§³Ö¡£¡£¡£¡£¡£¡£¡£¡£ÆäÔøÔÚÃÀ¹ú¶¾Àíѧ»áµÄ±±ÃÀ»ªÈ˶¾Àíѧ»áµ£µ±»á³¤ºÍÄÉÃ×¶¾Àíѧ»á·Ö»áµ£µ±×¨ÒµÎ¯Ô±»áÀíÊ¡£¡£¡£¡£¡£¡£¡£¡£
| ±Ú±¨Õ¹Ê¾£¨Poster£©¿ÉÒÔÔÚչλ1351Ãâ·Ñ»ñÈ¡±Ú±¨ÄÚÈÝ
01
±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º4254/Q770
±Ú±¨Ö÷Ì⣨Abstract Title£©£ºAnalysis of Toxicity Characteristics of GLP-1 Receptor Agonists in Non-clinical Safety Evaluation£¨GLP-1ÊÜÌ弤¶¯¼ÁÔÚ·ÇÁÙ´²Çå¾²ÐÔÆÀ¼ÛÖе;ÐÔÌØÕ÷ÆÊÎö£©
±Ú±¨¼ò½é£¨Introduction£©£ºÒȸßѪÌÇËØÑùëÄ-1ÊÜÌ弤¶¯¼Á£¨GLP-1RA£©ÊÇÒ»ÀàеĽµÌÇÒ©Î£¬£¬£¬£¬£¬£¬£¬¿ÉÒÔͨ¹ý¼¤»îGLP-1ÊÜÌåÀ´½µµÍѪÌǺÍ×ÊÖú¼õ·Ê¡£¡£¡£¡£¡£¡£¡£¡£GLP-1RA»¹¾ßÓпØÖÆÌåÖØ¡¢¸ÄÉÆ·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎµÈ¶àÖÖÁÙ´²Òæ´¦£¬£¬£¬£¬£¬£¬£¬£¬ÕýÖð½¥³ÉΪÖÎÁÆÌÇÄò²¡µÄÖ÷Òª´¦·½Ò©¡£¡£¡£¡£¡£¡£¡£¡£±¾Ñо¿ÒÔ×¢Éä¼ÁΪÖ÷µÄGLP-1RA¶¾ÐÔÑо¿Ð§¹û¾ÙÐÐ×ܽᣬ£¬£¬£¬£¬£¬£¬£¬²¢ÍŽáÒÑÉÏÊÐͬÀà²úÆ·µÄ¶¾ÐÔÌØµã£¬£¬£¬£¬£¬£¬£¬£¬Îª¸ÃÀà²úÆ·µÄ·ÇÁÙ´²Çå¾²ÐÔÆÀ¼ÛºÍ¶¾ÐÔÆÊÎöÌṩ²Î¿¼ÒÀ¾Ý¡£¡£¡£¡£¡£¡£¡£¡£
±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm
±Ú±¨°å¿é£¨Session Title£©£ºSafety Assessment£ºNon-pharmaceutical
±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºÂí½ðÁá Jinling Ma
02
±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º4166/N676
±Ú±¨Ö÷Ì⣨Abstract Title£©£ºIn vivo Imaging and Quantification of Retinal and Choroidal Vasculature in Cynomolgus Monkeys using Optical Coherence Tomography Angiography£¨¹âѧÏà¹Ø¶Ï²ãɨÃèѪ¹ÜÔìÓ°ÔÚʳзºïÊÓÍøÄ¤ºÍÂöÂçĤѪ¹ÜµÄÌåÄÚ³ÉÏñºÍ¶¨Á¿Ñо¿£©
±Ú±¨¼ò½é£¨Introduction£©£º¹âѧÏà¹Ø¶Ï²ãѪ¹ÜÔìÓ°£¨OCTA£©ÊÇÒ»ÖÖеÄÎÞ´´ÊÖÒÕ£¬£¬£¬£¬£¬£¬£¬£¬ÓÃÓÚ¿ÉÊÓ»¯ÊÓÍøÄ¤ºÍÂöÂçĤ΢Ѫ¹Üϵͳ¡£¡£¡£¡£¡£¡£¡£¡£·ÇÈËÁ鳤ÀදÎïÓÉÓÚÆäÓëÈËÑÛµÄÆÊ½âºÍÒÅ´«ÏàËÆÐÔ¶ø±»ÆÕ±éÓ¦ÓÃÓÚÁÙ´²Ç°ÑÛ¿ÆÑо¿¡£¡£¡£¡£¡£¡£¡£¡£±¾Ñо¿µÄÄ¿µÄÊDZíÕ÷NHPµÄOCTAÌØÕ÷£¬£¬£¬£¬£¬£¬£¬£¬²¢½¨Éè±ê×¼»¯µÄÒªÁìÀ´ÆÀ¹ÀNHPµÄÊÓÍøÄ¤Ñª¹Ü¸´ºÏÎ£¬£¬£¬£¬£¬£¬£¬ÓÃÓÚÁÙ´²Ç°ÑÛ¿ÆÑо¿¡£¡£¡£¡£¡£¡£¡£¡£
±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm
±Ú±¨°å¿é£¨Session Title£©£ºOcular Toxicology
±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºÐ»ÍòÀ¤ Wankun Xie
03
±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3670/A130
±Ú±¨Ö÷Ì⣨Abstract Title£©£ºPharmacodynamic Effect and Toxicity Study of Multi-specific Antibodies in a Humanized Mouse Model with Tumor-Bearing£¨¶àÌØÒìÐÔ¿¹ÌåÔÚÈËÔ´»¯Ð¡ÊóºÉÁöÄ£×ÓÖеÄҩЧѧЧӦ¼°¶¾ÐÔÑо¿£©
±Ú±¨¼ò½é£¨Introduction£©£ºTϸ°û½ÓºÏÎï£¨Ë«ÌØÒìÐÔ¿¹Ì壩¼ÈÄÜÓëÖ×Áöϸ°ûÍŽᣬ£¬£¬£¬£¬£¬£¬£¬Ò²ÄÜÓëÃâÒßϸ°ûÈçTϸ°ûÍŽᣬ£¬£¬£¬£¬£¬£¬£¬Í¨¹ý˫͎áÖ¸µ¼ÃâÒßϸ°ûɱËÀÖ×Áöϸ°û¡£¡£¡£¡£¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬£¬Ë«ÌØÒìÐÔ¿¹ÌåºÜÈÝÒ×½øÈëÒ»ÖÖ±»ºÄ¾¡µÄ״̬£¬£¬£¬£¬£¬£¬£¬£¬µ¼Ö¼¤»îµÄTϸ°ûÓÉÓÚȱ·¦¹²´Ì¼¤·Ö×Ó¶øÔÚÓ¦Óú󲻾ñäµÃÎÞ·´Ó¦¡£¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»ùÓÚÒÔÉÏÊӲ죬£¬£¬£¬£¬£¬£¬£¬ÎÒÃÇÖÆ±¸ÁËÌí¼Ó¹²´Ì¼¤·Ö×ÓµÄÈýÌØÒìÐÔ¿¹Ì壬£¬£¬£¬£¬£¬£¬£¬×èÖ¹ÁËTϸ°û±»¼òµ¥Ðźż¤»î¶øËðʧÄÜÁ¦£¬£¬£¬£¬£¬£¬£¬£¬ÓÐÍûÌá¸ßtϸ°û¶ÔÖ×Áöϸ°ûµÄɱÉËЧ¹û¡£¡£¡£¡£¡£¡£¡£¡£±¾Ñо¿ÆÀ¼ÛÁËCD3/CD20/CD28¿¹ÌåºÍBlinatumomabÀàËÆÎïµ¥¿Ë¡¿¹Ìå¶ÔRajiÔØÁöNPGÈËÔìѪ¸Éϸ°û£¨HSC£©ÖØÐÞСÊóÄ£×ӵĿ¹°©Ð§¹ûºÍDZÔÚ¶¾ÐÔ£¬£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°ËüÃÇÔÚÌåÍâ¶ÔÈËÍâÖÜѪµ¥ºËϸ°û£¨PBMCs£©»î»¯µÄÓ°Ïì¡£¡£¡£¡£¡£¡£¡£¡£
±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm
±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I
±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºLi Sun
04
±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3644/A102
±Ú±¨Ö÷Ì⣨Abstract Title£©£ºComparison of Cytokine Release Syndrome induced by Chimeric Antigen Receptor T Cells in Humanized NOG-EXL mice and NOG mice£¨Ç¶ºÏ¿¹ÔÊÜÌåTϸ°ûÓÕµ¼ÈËÔ´»¯NOG-EXLСÊóºÍNOGСÊóϸ°ûÒò×ÓÊÍ·Å×ÛºÏÕ÷µÄ½ÏÁ¿£©
±Ú±¨¼ò½é£¨Introduction£©£ºTϸ°û½éµ¼µÄ°©Ö¢ÃâÒßÁÆ·¨£¬£¬£¬£¬£¬£¬£¬£¬°üÀ¨Ç¶ºÏ¿¹ÔÊÜÌ壨CAR£©Tϸ°ûÁÆ·¨ºÍÕÙļϸ°û¶¾ÐÔTÁܰÍϸ°û£¨CTLs£©µ½°©Ï¸°ûµÄË«ÌØÒìÐÔ¿¹Ì壬£¬£¬£¬£¬£¬£¬£¬Ö±½Óʶ±ð°©Ï¸°ûÍâò¿¹Ô£¬£¬£¬£¬£¬£¬£¬£¬¶ø²»ÊÜMHCÏÞÖÆ¡£¡£¡£¡£¡£¡£¡£¡£Ö»¹ÜÔÚÁÙ´²Ó¦ÓÃÖжԶñÐÔÖ×Áö¾ßÓÐÏÔÖøµÄÁÆÐ§£¬£¬£¬£¬£¬£¬£¬£¬µ«CAR - Tϸ°ûÁÆ·¨¾³£°éÓÐÑÏÖØµÄϸ°ûÒò×ÓÊÍ·Å×ÛºÏÕ÷£¨CRS£©£¬£¬£¬£¬£¬£¬£¬£¬ÕâÊÇCAR - Tϸ°ûÃâÒßÁÆ·¨µÄÈõµãÖ®Ò»¡£¡£¡£¡£¡£¡£¡£¡£ÎÒÃÇ֮ǰ±¨µÀÁËÊä×¢µÄCAR-Tϸ°ûÔÚºÉÁöNOGСÊóÖеĻºÍÖ×Áö¸ººÉµÄÏûÍË£¬£¬£¬£¬£¬£¬£¬£¬ÆäÖÐѪÇåÖÐÈËÀàϸ°ûÒò×ÓµÄÊÍ·ÅÊÇÐþÃîµÄ¡£¡£¡£¡£¡£¡£¡£¡£¿£¿£¿£¿£¿£Ë¼Á¿µ½¶àÖÖÈËÀàÃâÒßϸ°û¼ÓÈëÁËCRS£¬£¬£¬£¬£¬£¬£¬£¬Òò´ËÎÒÃÇÆÀ¹ÀÁËÈËÀàÔìѪ¸Éϸ°û£¨HSC£©ÒÆÖ²ºÍÖ×ÁöÖ²ÈëNOG-EXLСÊóµÄCRS¡£¡£¡£¡£¡£¡£¡£¡£ÔÚÈËÔ´»¯NOG-EXLÄ£×ÓÖУ¬£¬£¬£¬£¬£¬£¬£¬ÎÒÃÇ·¢Ã÷СÊóÍâÖÜѪÖÐ×¢ÉäCAR-Tϸ°ûºó£¬£¬£¬£¬£¬£¬£¬£¬ÈËTϸ°û¡¢Bϸ°ûºÍ¹ÇËèϸ°ûÀ©Ôö£¬£¬£¬£¬£¬£¬£¬£¬ÈËϸ°ûÒò×ÓˮƽÉý¸ß¡£¡£¡£¡£¡£¡£¡£¡£
±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm
±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I
±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºYang Cao
05
±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3641/A101
±Ú±¨Ö÷Ì⣨Abstract Title£©£ºTherapeutic effects of anti-TNF-¦Á monoclonal antibody on cytokine release induced by CAR-T cells targeting CD22£¨¿¹TNF-¦Áµ¥¿Ë¡¿¹Ìå¶Ô°ÐÏòCD22µÄCAR-Tϸ°ûÓÕµ¼µÄϸ°ûÒò×ÓÊͷŵÄÖÎÁÆ×÷Óã©
±Ú±¨¼ò½é£¨Introduction£©£ºÖ»¹Üϸ°ûÒò×ÓÊÍ·Å×ÛºÏÕ÷£¨CRS£©ÊÇCAR-Tϸ°ûÖÎÁÆ×î³£¼ûµÄÁÙ´²¸±×÷Ó㬣¬£¬£¬£¬£¬£¬£¬µ«ÔÚʹÓÃÃâÒßȱÏÝСÊóÔØÁöÄ£×ÓµÄÁÙ´²Ç°Ñо¿ÖкÜÉÙ¼ûµ½¡£¡£¡£¡£¡£¡£¡£¡£µ±ÎÒÃÇÔÚNOG-RajiСÊóÄ£×ÓÖÐÆÀ¹Àcd22ÌØÒìÐÔCAR-Tϸ°û²úÆ·µÄÓÐÓÃÐÔºÍÇå¾²ÐÔʱ£¬£¬£¬£¬£¬£¬£¬£¬·¢Ã÷ÁËCAR-Tϸ°ûÏà¹ØµÄ¶¾ÐÔ·´Ó¦£¬£¬£¬£¬£¬£¬£¬£¬°üÀ¨¶ÌÔݵÄÌåÖØ¼õÇáºÍ¶¯ÎïéæÃü¡£¡£¡£¡£¡£¡£¡£¡£ÔÚËæºóµÄÊý¾ÝÆÊÎöÖУ¬£¬£¬£¬£¬£¬£¬£¬Òì³£Éý¸ßµÄTNF-¦Áˮƽ±»ÒÔΪÓëСÊóµÄÕâÖÖ¶¾ÐÔ·´Ó¦Óйء£¡£¡£¡£¡£¡£¡£¡£¿£¿£¿£¿£¿£¿¹Ö×Áö»µËÀÒò×Ó-¦Áµ¥¿Ë¡¿¹Ì壨°¢´ïľµ¥¿¹£©ÖÎÁÆ¿ÉÔÚ²»Ó°ÏìCAR-Tϸ°û¿¹Ö×Áö×÷ÓõÄÇéÐÎÏÂÞ׿¹Ð¡ÊóÌåÖØ¼õÇá²¢½µµÍéæÃüÂÊ¡£¡£¡£¡£¡£¡£¡£¡£lzyq88¹ÙÍøÑо¿Ð§¹ûÅú×¢£¬£¬£¬£¬£¬£¬£¬£¬ÍâÖÜѪTNF-¦ÁˮƽÉý¸ß¿ÉÄÜÊÇÕâÖÖCAR-Tϸ°û²úƷδÀ´µÄÁÙ´²¶¾ÐÔ±ê¼Ç£¬£¬£¬£¬£¬£¬£¬£¬TNF-¦ÁÖкÍÁÆ·¨¿ÉÄÜÊÇÔ¤·ÀºÍÖÎÁÆÇ±ÔÚÁÙ´²CRSµÄ¿ÉÐмƻ®¡£¡£¡£¡£¡£¡£¡£¡£
±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm
±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I
±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºYang Chen
06
±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3668-A128
±Ú±¨Ö÷Ì⣨Abstract Title£©£ºImmunogenicity Concerns in Preclinical Safety Evaluation of Biologics in Non-human Primates£¨ÉúÎïÖÆ¼ÁÁÙ´²Ç°Çå¾²ÐÔÆÀ¼ÛÖеÄÃâÒßÔÐÔÎÊÌ⡪¡ª·ÇÈËÀàÁ鳤Àࣩ
±Ú±¨¼ò½é£¨Introduction£©£º
Õë¶Ô¿ÉÈÜÉúÎï°ÐµãµÄµ¥¿Ë¡¿¹Ìå¡¢Ë«ÌØÒìÐÔ¿¹ÌåºÍÈÚºÏÂѰ׵ÈÉúÎïÒ©ÎK´óµØ¸ÄÉÆÁËÄÑÖÎÐÔ»òÓÐÊý²¡µÄҽѧÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£¡£·ÇÈËÁ鳤ÀදÎNon-human primate, NHPs£©¾ßÓÐÓÅÒìµÄҩЧѧ¡¢¶¾ÀíѧӰÏìºÍÐÄÀíЧӦչÍû¼ÛÖµ£¬£¬£¬£¬£¬£¬£¬£¬Òѱ»Ö¤ÊµÊÇÉúÎïÖÆ¼ÁÁÙ´²Ç°Çå¾²ÐÔÆÀ¹ÀµÄÖ÷Òª¶¯ÎïÎïÖÖ¡£¡£¡£¡£¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬£¬ÃâÒßÔÐÔÈÔÊÇ·ÇÈËÁ鳤ÀදÎï¾ÙÐÐÉúÎïÖÆ¼ÁÇå¾²ÐÔÆÀ¹ÀµÄÒ»¸öÖ÷ÒªÎÊÌ⣬£¬£¬£¬£¬£¬£¬£¬¿ÉÄÜ»áÓ°Ïì¶ÔÈËÀ಻Á¼·´Ó¦µÄÕ¹Íû¼ÛÖµ¡£¡£¡£¡£¡£¡£¡£¡£±¾Ñо¿Ö¼ÔÚÌá³öÉúÎïÖÆÆ·ÁÙ´²Ç°Çå¾²ÐÔÆÀ¼ÛÑо¿ÖÐÃâÒßÔÐÔʶ±ðºÍ¸ÉÔ¤»úÖÆµÄÏêϸ²ÎÊý»òÒªÁì¡£¡£¡£¡£¡£¡£¡£¡£
±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm
±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I
±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºÕÅÓÀ±óYongbin Zhang
07
±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3612-P767
±Ú±¨Ö÷Ì⣨Abstract Title£©£ºImmunogenicity Concerns in Preclinical Safety Evaluation of Biologics in Sprague-Dawley Rats£¨ÉúÎïÖÆ¼ÁÁÙ´²Ç°Çå¾²ÐÔÆÀ¼ÛÖеÄÃâÒßÔÐÔÎÊÌ⡪¡ªSD´óÊó£©
±Ú±¨¼ò½é£¨Introduction£©£º
½üÄêÀ´£¬£¬£¬£¬£¬£¬£¬£¬µ¥¿Ë¡¿¹Ìå¡¢Ë«ÌØÒìÐÔ¿¹Ìå¡¢ÈÚºÏÂѰ׵ÈÉúÎïÖÆ¼ÁµÄÉú³¤Îª¸ÄÉÆÐÄѪ¹Üϵͳ¡¢ºôÎüϵͳ¡¢°©Ö¢¡¢ÔìѪϵͳ¼²²¡¡¢×ÔÉíÃâÒßÐÔ¼²²¡µÈÖÖÖÖ¼²²¡µÄҽѧÖÎÁÆ×ö³öÁËÖØ´óТ˳¡£¡£¡£¡£¡£¡£¡£¡£ÓÃSD´óÊó¾ÙÐж¯ÎïʵÑéÊÇÉúÎïÖÆ¼ÁÇå¾²ÐÔÆÀ¼ÛµÄ³£ÓúÍÓмÛÖµµÄ¹¤¾ß¡£¡£¡£¡£¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬£¬µ±ÔÚ´óÊóÖоÙÐÐÉúÎïÖÆ¼ÁµÄÇå¾²ÐÔÆÀ¹ÀÑо¿Ê±£¬£¬£¬£¬£¬£¬£¬£¬ÃâÒßÔÐÔÈÔÈ»ÊÇÒ»¸öÎÊÌâºÍ/»òÌôÕ½£¬£¬£¬£¬£¬£¬£¬£¬Õâ¿ÉÄÜ»áË𺦶ÔÈËÀ಻Á¼·´Ó¦µÄÕ¹ÍûÖµ¡£¡£¡£¡£¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬£¬´óÊó¶ÔÈËÌåҩЧѧºÍ¶¾ÀíѧӰÏìȷʵÓкܺõÄÕ¹Íû¼ÛÖµ¡£¡£¡£¡£¡£¡£¡£¡£±¾×ÛÊöµÄÄ¿µÄÊÇÆÀ¹ÀÉúÎïÖÆÆ·¶¾ÐÔÑо¿µÄÁÙ´²Ç°Êý¾Ý£¬£¬£¬£¬£¬£¬£¬£¬ÒÔÑо¿ÉúÎïÖÆÆ·µÄÃâÒßÔÐÔ¡£¡£¡£¡£¡£¡£¡£¡£
±Ú±¨ÏÈÈÝʱ¼ä£¨Date & time£©£º2025Äê3ÔÂ17ÈÕ 09:15-11:45£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 17th (Mon), 9:15-11:45 am
±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I
±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºÕÅÇÕÃ÷Luke Zhang


